CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.Yi Lin, Sundar Jagannath, Andrzej Jakubowiak et al.|Journal of Clinical Oncology|2023Cited by 117
Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI.Sundar Jagannath, Thomas Martin, Jesús G. Berdeja et al.|Journal of Clinical Oncology|2022Cited by 14